Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain.
Cytotherapy. 2009;11(8):1041-51. doi: 10.3109/14653240903191719.
The aim of this study was to compare prospectively the vasculogenic capacity of two cell sources, monocytes and CD133+ cells.
Cells were obtained from healthy donors by adherence or magnetic selection. Animals studies were performed in a model of hind limb ischemia and different groups were established according to type and number of cells infused. Revascularization was measured by sequential blood flow analysis using a laser Doppler device and by assessing capillary density in the ischemic muscles. In order to locate the infused cells, immunofluorescence and immunocytochemistry techniques were performed and analyzed by light and confocal microscopy.
During the study period there was a significant improvement in both limb perfusion and capillary density in mice treated with either human monocytes or CD133+ cells (P<0.05) compared with non-treated mice. No cells were detected as incorporated into the vessels when 1 x 10(5) cells were used but with higher doses (1 x 10(6)) a few human cells were observed integrated into the vessels in both groups of treated mice. Supernatants of both cell types showed vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and platelet-derived growth factor- AB (PDGF-AB) expression.
Treatment with human monocytes or CD133+ cells improves blood perfusion and capillary density in a murine model and both cell types seem to stimulate vasculogenesis in a fairly similar way.
本研究旨在前瞻性比较两种细胞来源（单核细胞和 CD133+细胞）的血管生成能力。
通过贴壁或磁选从健康供者中获得细胞。动物研究在下肢缺血模型中进行，并根据输注的细胞类型和数量建立不同的组别。通过激光多普勒设备进行序贯血流分析和评估缺血肌肉中的毛细血管密度来测量再血管化。为了定位输注的细胞，进行了免疫荧光和免疫细胞化学技术，并通过光镜和共聚焦显微镜进行分析。
在研究期间，与未治疗的小鼠相比，接受人单核细胞或 CD133+细胞治疗的小鼠的肢体灌注和毛细血管密度均有显著改善（P<0.05）。当使用 1 x 10(5)个细胞时，未检测到细胞整合到血管中，但使用更高剂量（1 x 10(6)）时，在两组治疗的小鼠中观察到少数人细胞整合到血管中。两种细胞类型的上清液均显示血管内皮生长因子（VEGF）、表皮生长因子（EGF）和血小板衍生生长因子-AB（PDGF-AB）的表达。
人单核细胞或 CD133+细胞的治疗可改善小鼠模型中的血液灌注和毛细血管密度，并且两种细胞类型似乎以相当相似的方式刺激血管生成。
